Gilbert Kliman Sells 5,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 5,000 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. This trade represents a 12.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Glaukos Stock Down 1.1%

GKOS stock traded down $1.58 during trading hours on Monday, reaching $142.43. 814,291 shares of the stock were exchanged, compared to its average volume of 799,557. The firm’s 50-day moving average is $117.71 and its 200-day moving average is $112.10. The company has a market cap of $8.37 billion, a price-to-earnings ratio of -43.42 and a beta of 0.94. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $148.11.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The company’s revenue was up 41.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.22) EPS. On average, equities research analysts expect that Glaukos Corporation will post -0.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on GKOS. Stifel Nicolaus set a $170.00 target price on Glaukos in a report on Thursday, April 30th. Wells Fargo & Company increased their target price on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Wall Street Zen upgraded Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Citigroup increased their target price on Glaukos from $135.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $144.42.

Hedge Funds Weigh In On Glaukos

Several hedge funds have recently modified their holdings of the stock. Wealth Alliance LLC grew its holdings in shares of Glaukos by 4.5% in the 1st quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock valued at $247,000 after acquiring an additional 98 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Glaukos by 9.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $158,000 after acquiring an additional 122 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares in the last quarter. CWM LLC grew its holdings in shares of Glaukos by 25.2% in the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock valued at $80,000 after acquiring an additional 143 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Glaukos by 1.7% in the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after acquiring an additional 144 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.